This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Positive opinions based on significant survival benefit
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
Subscribe To Our Newsletter & Stay Updated
